scholarly journals Effective Genetic Therapy of Established Medullary Thyroid Carcinomas with Murine Interleukin-2: Dissemination and Cytotoxicity Studies in a Rat Tumor Model*

Endocrinology ◽  
1999 ◽  
Vol 140 (5) ◽  
pp. 2152-2158 ◽  
Author(s):  
Rusheng Zhang ◽  
Francis H. Straus ◽  
Leslie J. DeGroot
Keyword(s):  
Interleukin 2 ◽  
Tumor Model ◽  
Genetic Therapy ◽  
Medullary Thyroid ◽  
Thyroid Carcinomas ◽  
Cytotoxicity Studies ◽  
Rat Tumor Model ◽  
Medullary Thyroid Carcinomas ◽  
Rat Tumor

scholarly journals Innovative strategies for the treatment of thyroid cancer

2000 ◽  
pp. 15-24 ◽  
Author(s):  
C Schmutzler ◽  
J Koehrle
Keyword(s):  
Gene Therapy ◽  
Immune Response ◽  
Thyroid Cancer ◽  
Standard Procedure ◽  
Interleukin 2 ◽  
Treatment Modalities ◽  
Medullary Thyroid ◽  
Thyroid Carcinomas ◽  
Radioiodide Therapy ◽  
Medullary Thyroid Carcinomas

Normally, thyroid cancer is a disease with a good prognosis, but about 30% of the tumours dedifferentiate and may finally develop into highly malignant anaplastic thyroid carcinomas with a mean survival time of less than 8 months. Due to the loss of thyroid-specific functions associated with dedifferentiation, these tumours are inaccessible to standard therapeutic procedures such as radioiodide therapy and thyroxine-mediated thyrotrophin suppression. Medullary thyroid carcinomas are also highly aggressive. Here, therapy is limited to surgery, and no alternative is left if patients do not respond to this standard procedure. Obviously, new approaches would be desirable. Several novel approaches are currently being tested for the treatment of thyroid cancer. Many of them utilise methods of gene therapy, but follow different strategies: (1) reintroduction of the tumour suppressor p53 into a background lacking functional p53; (2) suicide gene therapy with ganciclovir and a transduced gene for herpes simplex virus thymidine kinase controlled by the thyroglobulin promoter; (3) strengthening of the antitumour immune response by expression of an adenovirus-delivered interleukin-2 (IL-2) gene; (4) induction of an immune response by DNA vaccination against the tumour marker calcitonin; (5) transduction of the thyroid sodium/iodide transporter gene to make tissues that do not accumulate iodide treatable by radioiodide therapy; (6) blocking of the expression of the oncogene c-myc by antisense oligonucleotides. While these approaches are still tested in vitro or in animal models, first results from pilot studies concerning other novel treatment modalities are available: (7) radioimmunotherapy exploits the carcinoembryonic antigen expressed on medullary thyroid carcinomas to target a radiolabelled antibody to the tumour; and (8) retinoic acid is used for a redifferentiation therapy in the case of thyroid cancer. Hopefully, one or the other of these novel strategies may probably extend after some time the current therapeutic repertoire for thyroid cancers and provide a perspective for otherwise untreatable patients.

The CCK2-receptor is expressed in human medullary thyroid carcinomas as well as in normal thyroid tissue

2001 ◽  
Vol 120 (5) ◽  
pp. A507-A507
Author(s):  
M BLAEKER ◽  
A WEERTH ◽  
L JONAS ◽  
M TOMETTEN ◽  
M SCHUTZ ◽  
...  
Keyword(s):  
Thyroid Tissue ◽  
Normal Thyroid Tissue ◽  
Normal Thyroid ◽  
Medullary Thyroid ◽  
Thyroid Carcinomas ◽  
Cck2 Receptor ◽  
Medullary Thyroid Carcinomas

Antisense TGF-?2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model

2001 ◽  
Vol 8 (1) ◽  
pp. 32-37
Author(s):  
Melinda Maggard ◽  
Lingzhong Meng ◽  
Bibo Ke ◽  
Rene Allen ◽  
Lara Devgan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Model ◽  
Rat Tumor Model ◽  
Rat Tumor

scholarly journals Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?

Radiology ◽  
2010 ◽  
Vol 257 (3) ◽  
pp. 685-696 ◽  
Author(s):  
Wei Yang ◽  
Muneeb Ahmed ◽  
Mostafa Elian ◽  
El-Shymma A. Hady ◽  
Tatyana S. Levchenko ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Tumor Model ◽  
Percutaneous Radiofrequency Ablation ◽  
End Point ◽  
Rat Tumor Model ◽  
Rat Tumor
Sign in / Sign up

Export Citation Format

Share Document